MX382409B - Variantes de proteinas de unión al factor h y métodos de uso de estas. - Google Patents

Variantes de proteinas de unión al factor h y métodos de uso de estas.

Info

Publication number
MX382409B
MX382409B MX2017001038A MX2017001038A MX382409B MX 382409 B MX382409 B MX 382409B MX 2017001038 A MX2017001038 A MX 2017001038A MX 2017001038 A MX2017001038 A MX 2017001038A MX 382409 B MX382409 B MX 382409B
Authority
MX
Mexico
Prior art keywords
methods
factor
binding proteins
variants
proteins
Prior art date
Application number
MX2017001038A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001038A (es
Inventor
Peter T Beernink
Original Assignee
Childrens Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital & Res Center At Oakland filed Critical Childrens Hospital & Res Center At Oakland
Publication of MX2017001038A publication Critical patent/MX2017001038A/es
Publication of MX382409B publication Critical patent/MX382409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017001038A 2014-07-23 2015-07-22 Variantes de proteinas de unión al factor h y métodos de uso de estas. MX382409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017001038A MX2017001038A (es) 2018-02-09
MX382409B true MX382409B (es) 2025-03-13

Family

ID=55163727

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001038A MX382409B (es) 2014-07-23 2015-07-22 Variantes de proteinas de unión al factor h y métodos de uso de estas.
MX2023000204A MX2023000204A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2021005373A MX2021005373A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023000204A MX2023000204A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2021005373A MX2021005373A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.

Country Status (15)

Country Link
US (10) US10266572B2 (https=)
EP (2) EP4074726A3 (https=)
JP (4) JP6796057B2 (https=)
KR (2) KR102761870B1 (https=)
CN (3) CN119613509A (https=)
AU (5) AU2015292615B2 (https=)
BR (1) BR112017001417B1 (https=)
CA (2) CA3212723A1 (https=)
CO (1) CO2017000558A2 (https=)
CR (1) CR20170020A (https=)
ES (1) ES2922554T3 (https=)
MX (3) MX382409B (https=)
NZ (2) NZ766005A (https=)
RU (1) RU2714248C2 (https=)
WO (1) WO2016014719A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
KR101855139B1 (ko) 2016-11-16 2018-05-08 주식회사 케이엠더블유 Mimo 안테나에서의 캘리브레이션
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2026072910A1 (en) 2024-09-27 2026-04-02 Sanofi Pasteur Inc. Anti-meningococcal antibodies for in vitro immunoassay

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CN101160412A (zh) 2005-02-14 2008-04-09 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CN102356089B (zh) * 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2010027872A1 (en) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis
EP2331562A4 (en) 2008-09-03 2012-07-04 Childrens Hosp & Res Ct Oak PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
CA2759400A1 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
AU2011300409B2 (en) * 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
JP6002763B2 (ja) 2011-07-07 2016-10-05 デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フェーウェーエス グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
MY198910A (en) * 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CN105431167A (zh) 2013-08-02 2016-03-23 奥克兰儿童医院及研究中心 非天然发生因子h结合蛋白(fhbp)及其使用方法
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
EP3169357B1 (en) * 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
KR102761870B1 (ko) * 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
CO2017000558A2 (es) 2017-06-20
AU2025202774A1 (en) 2025-05-08
US12129282B2 (en) 2024-10-29
CN106715464A (zh) 2017-05-24
US20250136648A1 (en) 2025-05-01
AU2019264600A1 (en) 2019-12-05
BR112017001417B1 (pt) 2023-11-07
KR102752259B1 (ko) 2025-01-13
EP3172224B1 (en) 2022-06-29
CR20170020A (es) 2017-08-10
NZ766003A (en) 2024-01-26
JP7719046B2 (ja) 2025-08-05
US20170183384A1 (en) 2017-06-29
JP6796057B2 (ja) 2020-12-02
WO2016014719A1 (en) 2016-01-28
CN119613509A (zh) 2025-03-14
US12269849B2 (en) 2025-04-08
CN106715464B (zh) 2021-03-16
CN112851768A (zh) 2021-05-28
CA3212723A1 (en) 2016-01-28
MX2017001038A (es) 2018-02-09
US20200109179A1 (en) 2020-04-09
MX2023000204A (es) 2023-02-09
EP3172224A1 (en) 2017-05-31
US20240101610A1 (en) 2024-03-28
AU2019264600B2 (en) 2021-04-01
US20190225655A1 (en) 2019-07-25
US10836799B2 (en) 2020-11-17
KR20170028442A (ko) 2017-03-13
US20240025951A1 (en) 2024-01-25
RU2020105192A (ru) 2020-02-12
AU2015292615B2 (en) 2019-10-24
US11834476B2 (en) 2023-12-05
RU2017104742A (ru) 2018-08-29
KR102761870B1 (ko) 2025-02-05
RU2714248C2 (ru) 2020-02-13
EP4074726A2 (en) 2022-10-19
US20210340191A1 (en) 2021-11-04
EP4074726A3 (en) 2022-11-23
US10487122B2 (en) 2019-11-26
KR20230155595A (ko) 2023-11-10
JP7221917B2 (ja) 2023-02-14
NZ766444A (en) 2024-01-26
ES2922554T3 (es) 2022-09-16
CA2955802C (en) 2023-10-31
US20200095288A1 (en) 2020-03-26
AU2025202774A9 (en) 2026-03-05
EP3172224A4 (en) 2018-04-18
AU2021203828B2 (en) 2023-04-13
JP2023011916A (ja) 2023-01-24
AU2015292615A1 (en) 2017-03-16
RU2017104742A3 (https=) 2019-02-27
NZ729206A (en) 2022-07-01
AU2023204391A1 (en) 2023-08-03
US10995122B2 (en) 2021-05-04
JP2025108722A (ja) 2025-07-23
NZ766005A (en) 2024-03-22
BR112017001417A2 (pt) 2017-11-21
MX2021005373A (es) 2021-07-06
JP2021000121A (ja) 2021-01-07
US20250154206A1 (en) 2025-05-15
CA2955802A1 (en) 2016-01-28
US11673920B2 (en) 2023-06-13
US10266572B2 (en) 2019-04-23
AU2023204391B2 (en) 2025-01-23
AU2021203828A1 (en) 2021-07-08
JP2017522877A (ja) 2017-08-17
US20210101942A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
MX382409B (es) Variantes de proteinas de unión al factor h y métodos de uso de estas.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
BR112016029579A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
CR20140585A (es) Proteinas de union a antigeno st2
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2016016886A (es) Anticuerpos anti-axl.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX2017015817A (es) Anticuerpos de union a tau.
BR112016018313A8 (pt) Moléculas de ligação multiespecíficas iga
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
BR112017015159A2 (pt) preparação e uso de produtos plaquetários